Lord, Abbett & Co
MDGL icon

Lord, Abbett & Co’s Madrigal Pharmaceuticals MDGL Stock Holding History

Lord, Abbett & Co’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$151M Buy
281,500
+38,774
+16% +$19.9M 0.43% 57
2026
Q1 		$127M Sell
242,726
-2,070
-0.8% -$989K 0.41% 62
2025
Q4 		$143M Buy
244,796
+142,653
+140% +$72.9M 0.44% 61
2025
Q3 		$46.8M Buy
102,143
+17,926
+21% +$6.69M 0.14% 174
2025
Q2 		$25.5M Sell
84,217
-33,807
-29% -$10.1M 0.08% 247
2025
Q1 		$39.1M Buy
118,024
+69,107
+141% +$22.7M 0.14% 180
2024
Q4 		$15.1M Buy
+48,917
New +$13.8M 0.05% 355
2024
Q2 		– Sell
-97,103
Closed -$25.9M – 567
2024
Q1 		$25.9M Buy
+97,103
New +$22.9M 0.08% 289
2023
Q3 		– Sell
-67,918
Closed -$15.7M – 560
2023
Q2 		$15.7M Sell
67,918
-107
-0.2% -$29K 0.05% 382
2023
Q1 		$16.5M Sell
68,025
-110,493
-62% -$30.1M 0.06% 379
2022
Q4 		$51.8M Buy
+178,518
New +$17.5M 0.19% 158
2018
Q3 		– Sell
-92,193
Closed -$25.8M – 864
2018
Q2 		$25.8M Buy
92,193
+31,993
+53% +$5.62M 0.08% 409
2018
Q1 		$7.03M Sell
60,200
-42,042
-41% -$5.19M 0.02% 671
2017
Q4 		$9.38M Buy
+102,242
New +$5.84M 0.03% 633

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Lord, Abbett & Co's MDGL Position: Q2 2026 in Review

Lord, Abbett & Co increased its Madrigal Pharmaceuticals (MDGL) stake by 16% in Q2 2026, buying an estimated $19.9M and bringing the position to 281,500 shares worth $151M. The position accounts for 0.43% of the portfolio, ranked #57.

Lord, Abbett & Co first reported a position in MDGL in Q4 2017 and has held it in 14 quarters since. 413 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

  • Lord, Abbett & Co held 281,500 shares of Madrigal Pharmaceuticals worth $151M as of Q2 2026.
  • Lord, Abbett & Co bought 38,774 Madrigal Pharmaceuticals shares in Q2 2026, an estimated $19.9M.
  • Madrigal Pharmaceuticals made up 0.43% of Lord, Abbett & Co's portfolio in Q2 2026, its #57 holding.
  • Lord, Abbett & Co first reported a position in Madrigal Pharmaceuticals in Q4 2017 and has held it in 14 quarters since.
  • 413 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Lord, Abbett & Co's 13F filing for Q2 2026, filed 14 Aug 2026.